Fixed-schedule Benzodiazepine Dosing vs Based on a CIWA-Ar Alcohol Protocol in Alcohol Detoxification.
NCT04777552 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50
Last updated 2021-03-02
Summary
Does the use of a symptom-triggered therapy (with assessment making use of a CIWA-Ar scale) decrease the total amount of benzodiazepines given to patients with alcohol dependence and are less patients still dependent on benzodiazepines on their departure in comparison with the use of a fixed-schedule dose of benzodiazepines?
Conditions
- Alcoholdependence
- CIWA-R
- Benzodiazepines
Interventions
- OTHER
-
diazepam (or equivalence if other benzodiazepine)
Sponsors & Collaborators
-
Universitair Ziekenhuis Brussel
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-10-31
- Primary Completion
- 2016-04-30
- Completion
- 2016-05-31
More Related Trials
-
New Therapeutic Strategies for the Treatment of Alcohol Use Disorders
NCT03028662 ·Status: COMPLETED ·Phase: NA
-
Drug Therapy for Alcohol Detoxification
NCT00000441 ·Status: COMPLETED ·Phase: PHASE4
-
Severe Alcohol-use Disorder: a tDCS and Response Inhibition Training Intervention
NCT03447054 ·Status: COMPLETED ·Phase: NA
-
Gabapentin vs Chlordiazepoxide for Ambulatory Alcohol Withdrawal
NCT01573052 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of High Dose Baclofen for Alcohol Dependence
NCT01980706 ·Status: COMPLETED ·Phase: PHASE2
-
Integrative Therapy in Alcoholism
NCT00159107 ·Status: COMPLETED ·Phase: PHASE4
-
Learning to Resist the Urge: Inhibition Training in Abstinent Patients With Alcohol Use Disorders
NCT02968537 ·Status: COMPLETED ·Phase: NA
-
Treating Alcohol Withdrawal With Oral Baclofen
NCT00597701 ·Status: COMPLETED ·Phase: NA
-
Effect of Anti-craving Medication on Cognitive Functions in Alcohol Dependence: an ERP Study
NCT02107352 ·Status: COMPLETED
-
Phosphatidylethanol-Based Contingency Management for Housing
NCT04038021 ·Status: COMPLETED ·Phase: NA
-
Acamprosate Treatment: Mechanisms of Action
NCT00004552 ·Status: COMPLETED ·Phase: PHASE2
-
Baclofen for the Treatment of Alcohol Dependence
NCT01266655 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Cognitive Retraining and Brain Stimulation for Alcohol Use
NCT02045108 ·Status: COMPLETED ·Phase: NA
-
PT150 Drug for Use in Alcohol Use Disorder
NCT06712602 ·Status: RECRUITING ·Phase: PHASE1
-
Donepezil and Cognitive Training for Alcohol Use Disorder (AUD)
NCT05042102 ·Status: RECRUITING ·Phase: PHASE2
-
Baclofen for Anxiety and Alcohol Use Disorder (AUD): an Open Label Study
NCT06835907 ·Status: RECRUITING ·Phase: NA
-
Corticotropin-Releasing Hormone Receptor 1 (CRH1) Antagonism in Anxious Alcoholics^
NCT01227980 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment of Alcohol Withdrawal Syndrome With Alpha-2 Agonists and/or Anticonvulsants
NCT05438641 ·Status: COMPLETED
-
Intravenous Alcohol Administration Using BrAc Method in Healthy Subjects With and Without a Family History of Alcoholism
NCT00612352 ·Status: COMPLETED ·Phase: NA
-
GABA Mechanisms Underlying the Vulnerability to Alcohol Dependence
NCT00611767 ·Status: COMPLETED ·Phase: NA
-
Treatment of Alcohol Withdrawal in Hospital Patients
NCT00249366 ·Status: COMPLETED ·Phase: PHASE4
-
Can Cognitive-bias Modification Training During Inpatient Alcohol Detoxification Reduce Relapse Rates Post-discharge?
NCT02634476 ·Status: COMPLETED ·Phase: NA
-
Sequence of Symptom Change During AUD or PTSD Treatment for Comorbid PTSD/AUD
NCT01663337 ·Status: UNKNOWN ·Phase: NA
-
Neurofeedback Training of Metacognition in Subjects With Alcohol Use Disorder. Disorder Induces Neural Modifications: an Event-related Potentials Study
NCT05913518 ·Status: RECRUITING ·Phase: NA
-
Investigation of the Efficacy of Acamprosate and Calcium in Comparison to Placebo as Validation of a Behavioural Test for Alcohol Dependence
NCT03634917 ·Status: COMPLETED ·Phase: PHASE3